A Phase II, Multi-center, Open-label, Repeat-dose Study of Lenalidomide (Revlimid) Plus Low-dose Dexamethasone in Patients With Refractory B Cell Lineage Acute Lymphoblastic Leukemia or in Relapse After 2 Lines of Treatment.
Phase of Trial: Phase II
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Dexamethasone; Lenalidomide
- Indications Acute lymphoblastic leukaemia
- Focus Therapeutic Use
- 08 May 2010 New trial record